Retour sur lavenir.net
   KBC ANCORA 83.900 € (+0,12 %)     AB INBEV 71.580 € (+3,05 %)     BEKAERT 39.850 € (-1,36 %)     SOLVAY 26.440 € (+0,99 %)     UCB 254.800 € (+0,16 %)     SYENSQO 67.100 € (+2,68 %)     KBC 121.600 € (+0,41 %)     MELEXIS 74.300 € (-6,42 %)     RECTICEL 11.400 € (+3,83 %)     D'IETEREN GROUP 177.100 € (-1,56 %)     ARGENX SE 810.400 € (-0,32 %)     AZELIS GROUP 9.875 € (-1,20 %)     ONWARD MEDICAL 2.505 € (-3,47 %)     SOFINA 228.600 € (-0,78 %)     UMICORE 20.700 € (-2,63 %)     BPOST 1.620 € (-2,41 %)     MONTEA 67.800 € (+0,89 %)     ELIA GROUP 138.000 € (0,00 %)     WDP 22.180 € (+0,73 %)     EVS 27.150 € (-0,37 %)     AEDIFICA 70.100 € (+1,30 %)     PROXIMUS 5.930 € (+2,86 %)     SHURGARD 26.700 € (+2,10 %)     TITAN S.A. 51.100 € (-1,73 %)     AGEAS 71.050 € (+0,50 %)     TUBIZE-FIN 219.400 € (+0,37 %)     CENERGY 23.000 € (-3,36 %)     JENSEN-GROUP 84.000 € (0,00 %)     BARCO 8.580 € (+1,06 %)     COLRUYT 37.040 € (+2,49 %)     WERELDHAVE BELGIUM 53.400 € (+1,14 %)     GBL 78.700 € (-0,06 %)     CARE PROPERTY INV. 12.680 € (+1,28 %)     XIOR 27.450 € (+1,29 %)     GIMV 45.100 € (-1,85 %)     CMB.TECH 13.440 € (-0,44 %)     ACKERMANS V.HAAREN 275.400 € (-1,36 %)     VGP 85.800 € (-1,15 %)     DEME GROUP 171.400 € (-1,61 %)     FAGRON 24.050 € (-0,82 %)     KINEPOLIS GROUP 36.100 € (+0,28 %)     DECEUNINCK 2.265 € (+0,89 %)     ASCENCIO 51.300 € (-0,39 %)     NYXOAH 1.536 € (-2,91 %)     ATENOR 1.645 € (+2,49 %)     ONTEX GROUP 2.415 € (+1,47 %)     TESSENDERLO 20.100 € (-0,50 %)     CFE 13.200 € (-1,86 %)     BELYSSE GROUP 0.520 € (-2,26 %)     SIPEF 91.100 € (+1,00 %)     VAN DE VELDE 30.100 € (+0,33 %)     LOTUS BAKERIES 11 420.000 € (+0,53 %)     IMMOBEL 22.200 € (-1,33 %)     BREDERODE 104.200 € (+0,19 %)     QUESTFOR GR-PRICAF 2.971 € (+0,03 %)     TINC 11.280 € (+0,36 %)     HOME INVEST BE. 19.140 € (0,00 %)     RETAIL ESTATES 69.500 € (+1,46 %)     CELYAD ONCOLOGY 0.228 € (0,00 %)     HYLORIS 4.280 € (-4,46 %)  
   APERAM 45.380 € (-1,00 %)     EXOSENS 59.450 € (-0,83 %)     ALSTOM 15.920 € (-1,49 %)     B.COM.PORTUGUES 1.081 € (+0,70 %)     PROSUS 39.305 € (+3,01 %)     ASML HOLDING 1 516.200 € (-6,89 %)     SHELL PLC 35.235 € (+3,15 %)     PHILIPS KON 24.820 € (+1,31 %)     AMG 33.060 € (-1,37 %)     DSM FIRMENICH AG 86.080 € (+3,31 %)     OSE IMMUNO 3.402 € (-4,97 %)     UNILEVER 55.430 € (+3,78 %)     ASM INTERNATIONAL 898.200 € (-6,86 %)     SCHNEIDER ELECTRIC 269.450 € (-3,20 %)     SOITEC 103.050 € (-12,96 %)     BE SEMICONDUCTOR 242.300 € (-6,12 %)     MAGNUM 16.588 € (+2,02 %)     ADYEN 864.900 € (-0,43 %)     SAFRAN 347.000 € (-2,83 %)     IMCD 83.580 € (-1,76 %)     STMICROELECTRONICS 59.310 € (-6,39 %)     EDP RENEWABLES 14.050 € (-1,68 %)     EIFFAGE 125.250 € (-1,22 %)     SANOFI 75.560 € (+1,41 %)     AKZO NOBEL 60.000 € (+0,50 %)     ARCELORMITTAL SA 56.440 € (-0,91 %)     UBISOFT ENTERTAIN 5.748 € (+1,20 %)     LIGHTON 6.100 € (-3,94 %)     UMG 18.870 € (+0,61 %)     HEINEKEN 77.440 € (+2,95 %)     AHOLD DEL 36.390 € (+2,68 %)     ESSILORLUXOTTICA 176.100 € (+2,03 %)     AALBERTS NV 39.400 € (-2,76 %)     INPOST 15.410 € (0,00 %)     RELX 28.840 € (+2,93 %)     CVC CAPITAL 13.440 € (+0,30 %)     KPN KON 4.249 € (+1,72 %)     WOLTERS KLUWER 59.840 € (+3,39 %)     AEGON 7.694 € (-0,41 %)     SBM OFFSHORE 31.460 € (+0,58 %)     NN GROUP 76.160 € (+0,53 %)     ASR NEDERLAND 67.220 € (+0,33 %)     PUBLICIS GROUPE SA 88.200 € (+2,13 %)     ABN AMRO BANK N.V. 38.640 € (+0,03 %)     EXOR NV 69.500 € (-0,29 %)     ING GROEP N.V. 28.515 € (-0,71 %)     FORVIA 9.216 € (-0,11 %)     AIRBUS 204.050 € (-2,55 %)     ONE EXPERIENCE 0.362 € (-5,97 %)     CAPGEMINI 93.740 € (+1,01 %)     RIBER 9.800 € (-10,26 %)     DASSAULT SYSTEMES 18.700 € (+1,49 %)     HAVAS 18.100 € (+0,56 %)     SES 8.015 € (-1,17 %)     PHARMING GROUP 1.244 € (+1,06 %)     ENGIE 27.450 € (+0,88 %)     COFACE 15.290 € (+0,66 %)     SAINT GOBAIN 79.000 € (-0,23 %)     DANONE 74.300 € (+2,48 %)     THALES 238.700 € (-1,00 %)  
SARTORIUS STED BIO
DIM - FR0013154002 - Euronext Paris
180,000 €  15:58
+0,33 %
31/03/2023 08:50

Sartorius Stedim Biotech SA: Sartorius Stedim Biotech to acquire Polyplus

Sartorius Stedim Biotech SA / Key word(s): Acquisition
Sartorius Stedim Biotech SA: Sartorius Stedim Biotech to acquire Polyplus

31-March-2023 / 08:50 CET/CEST

Aubagne, March 31, 2023

Sartorius Stedim Biotech to acquire Polyplus
  • France-based Polyplus is a provider of innovative upstream technologies for cell and gene therapies
  • Polyplus' transfection reagents and plasmids are key components in the manufacturing of viral vectors
  • Agreed purchase price of approximately 2.4 billion euros

Sartorius Stedim Biotech, a leading international partner of the biopharmaceutical industry, has signed an agreement to acquire Polyplus for approximately 2.4 billion euros from private investors, including ARCHIMED and WP GG Holdings IV B.V., an affiliate of Warburg Pincus.

Polyplus, with around 270 employees, develops and produces transfection as well as other DNA/RNA delivery reagents and plasmid DNA in high quality and GMP grade. These are key components in the production of viral vectors used in cell and gene therapies and other advanced medicinal therapeutic products. Recording significant growth rates, Polyplus is expected to generate sales revenue in the upper double-digit million-euro range and a very substantial EBITDA margin in 2023. The proposed transaction is subject to customary conditions, including completion of the information and consultation of the works’ council and approval by regulatory authorities and is expected to close during the third quarter of 2023.

Founded in 2001, Polyplus is based in Strasbourg, France, and has locations in France, Belgium, the U.S., and China. The company has been expanding its focus beyond transfection reagents through acquisitions in adjacent technologies like plasmid design, and protein and plasmid manufacturing, broadening its upstream portfolio for gene therapies as well as gene-modified cell therapies.

“The innovative solutions of Polyplus are highly complementary to our portfolio, in particular to our offering of cell culture media and critical components for the development and manufacture of advanced therapies, and there are also strong synergies with our portfolio of downstream solutions for the manufacture of gene therapeutics,” said René Fáber, member of the Board of Directors and CEO of Sartorius Stedim Biotech. “In the dynamically growing market for cell and gene therapies, viral vectors are needed to deliver the genes of interest into cells. The development pipeline of such therapies has been growing strongly and more and more are reaching major milestones. As a leading supplier of critical components to produce cell and gene therapies, Sartorius Stedim Biotech and Polyplus together will be excellently positioned to play a significant role in this dynamic field.”

“This contemplated acquisition is a major milestone in the history of Polyplus, and a recognition of its innovative upstream market leadership position and our highly talented Polyplus teams around the world,” said Mario Philips, CEO of Polyplus. “We would be excited to join forces with a world class bioprocess market leader as Sartorius Stedim Biotech. Our combined portfolios would create a unique ability to optimize the total process workflow to deliver unparalleled value for cell/gene and DNA/RNA therapy customers, in a strong effort to make these critical needed therapies more affordable.”

“We are both proud to have jointly supported Polyplus through a transformative period of growth, partnering with the company to successfully expand its product portfolio and execute a strong acquisition strategy,” said TJ Carella, Managing Director and Head of Healthcare, Warburg Pincus. “ARCHIMED has been a 7-year strategic partner and shareholder of Polyplus, hence we are glad company and team find such a good home for their next chapter,” said Denis Ribon, Chairman and Managing Partner, ARCHIMED.  “As active investors in life sciences, ARCHIMED and Warburg Pincus strongly believe in the impact that innovative pharmaceutical solutions can have on patients. With their shared mission in supporting the research and development of innovative solutions, we believe Sartorius Stedim Biotech would be the right partner for Polyplus and wish Mario and the Polyplus team the best in their next chapter,” added Ruoxi Chen, Managing Director, Warburg Pincus and Ludovic Alonzi, Principal, ARCHIMED.

The ultimate parent company Sartorius AG will receive a bridge loan facility from J.P. Morgan for a transitional period to finance the transaction. Sartorius intends to refinance this loan with long-term financing instruments which might also include an equity component.

Jefferies LLC acted as financial advisor and Kirkland & Ellis LLP provided legal counsel to Polyplus and its shareholders. William Blair acted as financial advisor and Milbank LLP and Jeantet provided legal counsel to Sartorius Stedim Biotech.


This press release contains forward-looking statements about the future development of the Sartorius Stedim Biotech Group. Forward-looking statements are subject to known and unknown risks, uncertainties and other factors that could cause actual results to differ materially from those expressed or implied by such statements. Sartorius Stedim Biotech assumes no liability for updating such statements in light of new information or future events. Sartorius Stedim Biotech shall not assume any liability for the correctness of this release. The French press release is the legally binding version.


A profile of Sartorius Stedim Biotech
Sartorius Stedim Biotech is a leading international partner of the biopharmaceutical industry. As a provider of innovative solutions, the company based in Aubagne, France, helps its customers to manufacture biotech medications safely, rapidly and economically. The shares of Sartorius Stedim Biotech S.A. are quoted on the Euronext Paris. The company has a strong global reach with manufacturing and R&D sites as well as sales entities in Europe, North America and Asia. Sartorius Stedim Biotech delivers significant organic growth and regularly expands its portfolio through acquisitions of complementary technologies. In fiscal 2022, the company generated sales revenue of around 3.5 billion euros. At the end of 2022, around 12,000 employees were working for customers around the globe.


Contact
Timo Lindemann
Corporate Communications
+49 (0)551 308 4724
timo.lindemann@sartorius.com

Follow Sartorius on Twitter and LinkedIn.

Dissemination of a Financial Wire News, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.

Language:English
Issuer:Sartorius Stedim Biotech SA
Avenue de Jouques
13781 Aubagne
France
Phone:+33 44 284 5600
E-mail:sartorius.presse@sartorius.com
Internet:www.sartorius-stedim.com
ISIN:FR0013154002
EQS News ID:1597763

 
End of Announcement - EQS News Service

1597763  31-March-2023 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1597763&application_name=news&site_id=symex

Source : Webdisclosure.com

© 2026 Tous droits réservés
Cotations différées d'au moins 15 minutes (Paris, Amsterdam, Bruxelles, Lisbonne).
Cotations à la clôture (Francfort, New-York, Londres, Zurich).
Flux de cotations : Euronext (Places Euronext et Cours des Devises).
Bourse : technologie Cote Boursière